Brian V Geisbrecht Lab

Brian V. Geisbrecht Laboratory at K-State. We use physical biochemistry methods to study the innate immune system. Papers not preprints.

[Brian V Geisbrecht Lab @BvgLab]

“from one stage to the next a greater amount of proenzyme is activated, and it may be suggested that the need to link the minute physical stimulus of surface contact with the final enzymatic explosion has resulted in the evolution of a biochemical amplifier” -RG Macfarlane, 1964

[The Journal of Immunology @J_Immunol]

In a #TopRead from @bvglab at @KStateResearch, data show that Efb-C binding to C3b exerts additional inhibitory effects on the central complement components beyond blocking formation of the C3 proconvertase alone. Learn more: https://t.co/hREXydH0dS.

[Aegean Conferences @AegeanConf]

Excited for the 18th Int'l Conference on Complement Therapeutics in Sissi, Crete, Greece 🇬🇷
A big thank you to our sponsors for their support. Your contribution helps bring together the complement community to share the latest advances in therapeutics and research.
There are still registration spots available at the early fee. Late-breaking abstract submissions are open, and trainees and young investigators are encouraged to apply for travel awards by April 15.
See our sponsors: https://t.co/15S9p574w5
#Complement #Therapeutics #Immunology #Conference #Crete #Greece #TravelAwards #CallForAbstracts

[Brian V Geisbrecht Lab @BvgLab]

New work from our lab published in @J_Immunol!
In a study led by @HuiquanDuan, we found that conformation-dependent recruitment of FHR-2 to the complement component C3b leads to synergistic inhibition of the terminal pathway. Link below 👇

https://t.co/75kmhxN2pE

[Brian V Geisbrecht Lab @BvgLab]

@KStateArtSci Thank you!

[Brian V Geisbrecht Lab @BvgLab]

@BethMontelone Thank you!

[Brian V Geisbrecht Lab @BvgLab]

Congratulations to Ying Zhang on the recent defense of her dissertation research concerning bacterial evasion of antibody mediated immune responses.

[Aegean Conferences @AegeanConf]

Registration now available online: 18th Int'l Conference on #ComplementTherapeutics https://t.co/Qh6d2a6nrx

[Brian V Geisbrecht Lab @BvgLab]

Many thanks to Jacob, Brewmaster of @aggievillebeer in #MHK for sharing his knowledge of the science behind beer making with @KStateBMB #Biochemistry and Society students this morning!

[Aegean Conferences @AegeanConf]

Congratulations to all the trainee awardees! Great Work! Great Science! 17th Int’l Conference on #Complement Therapeutics.

[Aegean Conferences @AegeanConf]

Program Available: 17th Int'l Conference on #ComplementTherapeutics from May 10-15, #Sissi #Crete #Greece
https://t.co/65Iqz9q8lJ

[Brian V Geisbrecht Lab @BvgLab]

Zymogen activation is a ubiquitous strategy for regulating enzyme activity. In our @jbiolchem paper led by @HuiquanDuan, we show that blocking this fundamental process is used to inhibit the first proteolytic event of the classical #complement pathway 👇
https://t.co/DT6LtvaCB4

[Brian V Geisbrecht Lab @BvgLab]

Congratulations to @HuiquanDuan for a successful defense of his PhD dissertation research on mechanisms of #complement inhibition! @KStateBMB

[Olivier George @brainaddiction]

It's clear that many do not understand what @NIH-funded research does to improve health. It's time to revive a study published 10 years ago that provides incredible information about this. link in the comment

Every single new drug approved by the FDA from 2010–2016 was built on NIH-funded research—that’s all 210 drugs. But what the public sees is just the tip of the iceberg.

Pharma takes credit for the final product, but beneath each drug developed, there are ~20 years of basic research, and 90% of the cost is from basic research funded by the NIH, which discovers drug targets, understands disease mechanisms, and creates life-saving treatments.

Figuring out how cancer evades the immune system, how addiction rewires the brain, and how heart disease develops is the role of the NIH, creating the foundation for the breakthrough drugs that come 20 years later, and the NIH does all that with only 0.8% of the US budget.

Without NIH, there would be no cancer immunotherapy, no anti-overdose medication, no anti-heart attack or stroke medication, no cutting-edge treatments.

If NIH funding is cut, the iceberg will melt. That means fewer cures, more suffering, and more lives lost.

The science beneath the surface keeps us afloat.
Invest in NIH. Invest in life

[Brian V Geisbrecht Lab @BvgLab]

@GattlingJr You are dating yourself, and increasing your suffering at the same time.

[Tanentzapf Lab @TanentzapfLab]

Yesterday a Nobel prize was given for alpha fold. Alpha fold could not exist without the Protein Data Bank (PDB), a public database funded by US taxpayers. Every structural biologist in the world that deposited their structure to the PDB indirectly helped train alpha fold.

[Brian V Geisbrecht Lab @BvgLab]

New work from our lab published in @jbiolchem!
👇
S. aureus Eap is a polyvalent inhibitor of neutrophil serine proteases - Journal of Biological Chemistry https://t.co/86U5TwE8Nf

Kudos to @Nitin_B_Mishra , @carsongido, and Tim Herdendorf for leading this effort! @KStateBMB

[Brian V Geisbrecht Lab @BvgLab]

First description of the self-amplifying nature of the #complement alternative pathway. Muller-Eberhard & Gotze, J. Exp. Med. 1972

[Brian V Geisbrecht Lab @BvgLab]

Congratulations to @Nitin_B_Mishra for a successful defense of his PhD dissertation research on #Staph protease inhibitors. @KStateBMB

[Brian V Geisbrecht Lab @BvgLab]

We participated in @AtomwiseInc #AIMS study published in @SciReports highlighting #AtomNet as a viable alternative to high-throughput screening! Read about the largest and most comprehensive virtual HTS campaign to date: https://t.co/oIuQoyU3bx #drugdiscovery #AI #pharma #biotech